Types of Cancer We Treat

Melanoma

As one of the first skin cancer treatment programs in New York City, we have long been at the forefront of melanoma research and care. We created the ABCDE screening system—now a standard diagnostic tool—to help identify melanoma at an early stage, when treatment is most effective.

Our dermatologists, dermatopathologists, oncologic surgeons, reconstructive plastic surgeons, medical oncologists, radiation oncologists, and pathologists combine their expertise to customize a treatment plan for you.

Our melanoma surgeons specialize in removing the cancer while preserving appearance and function, and our medical oncologists provide the latest targeted treatments, including genetically engineered injectable therapies.

Meet Our Doctors
Dr. Jeffrey Weber
Diagnosis
Melanoma Diagnosis
Surgery
Melanoma Surgery
Targeted Drugs & Immunotherapy
Melanoma Targeted Drugs and Immunotherapy
Radiation Therapy
Melanoma Radiation Therapy

Related News

Cancer Experts Share Updates in Immunology Advances
Read Story
Expert Discusses Taking Care of Your Skin This Summer
Read Story
Immunotherapy Provides New Options for Advanced Cancers
Read Story
Screening Guidelines for Skin Cancer & Melanoma, Explained
Read Story
Cancer Experts Discuss Immunotherapy’s Promises, Limitations
Read Story
Investigating the Molecular Basis of Metastatic Melanoma
Read Story

Clinical Trials and Research Studies

Phase 1/2

A Phase 1/2 Study Exploring the Safety Tolerability and Efficacy of INCAGN01949 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies

Learn More

Phase 1

Phase 1b Open-label Study of MK-7162 in Combination with Pembrolizumab (MK-3475) +/- other therapies in Participants with Advanced Solid Tumors

Learn More

Phase 1

A Phase 1 Open-Label Multicenter Study to Assess the Safety Tolerability and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors

Learn More

Phase 2

A Phase 2 Study of REGN2810 a Fully Human Monoclonal Antibody to Programmed Death-1 in Patients with Advanced Basal Cell Carcinoma who Experienced Progression of Disease on Hedgehog Pathway Inhibitor Therapy or were Intolerant of Prior Hedgehog Pathway Inhibitor therapy

Learn More
View All Related Clinical Trials (15)